Bringing science and development together through news and analysis

  • A patently raw deal from universities?

Shares

Once, universities saw patenting as militating against the interests of disinterested science and public health. Now a very different ethos prevails. Amid a heated debate over whether patents promote true innovation, universities are seeking revenue and courting commercialisation by taking out more patents than ever before.

In this article, Amy Kapczynski, E. Tyler Crone and Michael Merson of the Center for Interdisciplinary Research on AIDS at Yale University in New Haven, United States, say that when the patents involve life-saving drugs, this development becomes controversial. Patents and exclusive licences have been shown to boost prices and so prevent access to the drugs for many of the people who need them most, especially in poorer countries.

The way out of this ethical tangle could lie with access-friendly policies for intellectual property. A group of experts at Yale recently concluded that universities could help poorer countries by either refusing to patent drugs there, or offering non-exclusive licences. There is, say the authors, little profit at stake here for universities anyway — but everything to gain for the global common good.

Link to article in Science

Reference: Science, 301, 1629 (2003)

Republish
We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.